BackCuranex PharmaceuticalsCommon Stock Overview

Curanex PharmaceuticalsCommon Stock Long Term Debt

Latest long-term debt for CURX: $180K.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$181948.00
3028.40% YoYΔ $176132.00 vs prior year quarter

Peer trimmed avg / median

Loading

Curanex PharmaceuticalsCommon Stock Long Term Debt History

Loading

Curanex PharmaceuticalsCommon Stock vs. peers: Long Term Debt Comparison

Loading

Curanex PharmaceuticalsCommon Stock Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Curanex PharmaceuticalsCommon Stock (CURX) FAQ

As of the most recent data (June 2026), CURX shows a long-term debt of $180K. That compares with $5.8K in the prior-year period — up 3028.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CURX's long-term debt is now $180K (was $5.8K) — a 3028.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Curanex PharmaceuticalsCommon Stock is outperforming or lagging.

Tracking CURX's long-term debt over time shows whether Curanex PharmaceuticalsCommon Stock is scaling, shrinking, or reshaping that part of the business. The current reading is $180K That compares with $5.8K in the prior-year period — up 3028.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Curanex PharmaceuticalsCommon Stock's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $180K) with ownership activity and broader fundamentals.

Curanex PharmaceuticalsCommon Stock's long-term debt is $180K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.